This oxidative damage adversely affects neurological functions and our development, which can lead to mitochondrial dysfunction and a number of neurodegenerative diseases
One 2mg vial from a sealed box
If you have more questions
Built-In Exit Strategy The goal is to reduce or stop GLP-1 medication once your body is metabolically healthy
doi: 10.3389/fendo.2025.1570603 Received 03 February 2025 Accepted 29 April 2025 Published 21 May 2025 Volume 16 - 2025 Edited by Jared Rutter, The University of Utah, United States Reviewed by Steven Patterson, Glasgow Caledonian University, United Kingdom Elena Jimenez Marti, University of Valencia, Spain Nigel Irwin, Ulster University, United Kingdom Updates Copyright 2025 Koefoed-Hansen, Helsted, Kizilkaya, Lund, Rosenkilde and Gasbjerg